This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen Inc. (BIIB) Q1 Earnings Miss Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of -51.52% and 301.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Humana (HUM) Q4 Earnings Beat Estimates on Membership Growth
by Zacks Equity Research
Humana (HUM) is taking multiple initiatives like cost savings and others to generate $1 billion additional value to fund the Medicare Advantage business and boost Healthcare Services capabilities.
Here's Why Inovio (INO) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Inovio (INO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of 12.12% and 53.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Inovio Pharmaceuticals (INO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio Pharmaceuticals (INO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of -56.00% and -1.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Inovio Pharmaceuticals (INO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bear of the Day: Inovio Pharmaceuticals (INO)
by Madeleine Johnson
Is it too late to buy this coronavirus vaccine stock?
Best Buy, Inovio Pharmaceuticals, Volkswagen, Ericsson and Nokia highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Best Buy, Inovio Pharmaceuticals, Volkswagen, Ericsson and Nokia highlighted as Zacks Bull and Bear of the Day
Should You Buy Biotech ETFs Now?
by Neena Mishra
Biotech stocks are rallying this month; can the trend continue?
New Strong Sell Stocks for June 7th
by Zacks Equity Research
AL, FET, INO, SWKH, and WPG have been added to the Zacks Rank #5 (Strong Sell) List on June 7, 2021.
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of -50.00% and -44.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on the back of product launches and impressive geographical growth.
Do Options Traders Know Something About Inovio (INO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
QIAGEN (QGEN) Launches QIAseq Kit, Enhances COVID-19 Portfolio
by Zacks Equity Research
QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Is a Surprise Coming for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio (INO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio (INO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.